文献速递糖尿病

糖尿病患者对SARS-CoV-2多抗原的抗体反应:一项观察性队列研究

Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study.
PubMed 文献 · Diabetologia · 2020-10-08

该研究在509例确诊COVID-19患者中,用液相荧光素酶免疫沉淀法检测针对SARS-CoV-2多抗原的IgG、IgM和IgA反应。139例(27.3%)有糖尿病,糖尿病独立关联死亡风险(HR 2.32),但糖尿病患者的抗体反应在时机和滴度上与无糖尿病者相当,且不受血糖水平影响;RBD IgG阳性预测生存率。

要点

  • 糖尿病患者COVID-19死亡风险独立升高(HR 2.32)。
  • 糖尿病患者对SARS-CoV-2的抗体反应与无糖尿病者相当。
  • RBD IgG阳性与生存率改善相关,无论有无糖尿病。

核心结论

  • 高血糖患者COVID-19肺炎严重程度和死亡风险增加并非由体液免疫反应受损所致。
  • RBD IgG阳性与显著保护效应相关,对未来糖尿病患者的SARS-CoV-2疫苗效力可持谨慎乐观。

研究设计与样本

  • 观察性队列研究,纳入509例确诊COVID-19患者,前瞻性随访。
  • 使用液相荧光素酶免疫沉淀法检测针对SARS-CoV-2多抗原的IgG、IgM和IgA反应。

主要发现

  • 139例(27.3%)有糖尿病:90例(17.7%)入院前已诊断,49例(9.6%)入院时新诊断。
  • 糖尿病与炎症标志物升高、高凝状态、白细胞增多和中性粒细胞增多相关。
  • 糖尿病独立关联死亡风险(HR 2.32 [95% CI 1.44, 3.75],p = 0.001),调整年龄、性别和其他相关合并症后仍显著。
  • 较高血糖水平与死亡风险强关联,无论是否诊断糖尿病(HR 1.14 × 1.1 mmol/l [95% CI 1.08, 1.21],p < 0.001)。
  • 糖尿病患者对SARS-CoV-2的体液反应存在,且在时机和抗体滴度上与无糖尿病者相当,仅有微小差异,不受血糖水平影响。

临床怎么用

  • 糖尿病患者感染COVID-19后应积极控制血糖,因其与死亡风险独立相关。
  • 糖尿病患者不必担心抗体反应受损而影响疫苗应答,RBD IgG阳性提示保护性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The aim of the study was to characterise the humoral response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with diabetes. Demonstrating the ability to mount an appropriate antibody response in the presence of hyperglycaemia is relevant for the comprehension of mechanisms related to the observed worse clinical outcome of coronavirus disease 2019 (COVID-19) pneumonia in patients with diabetes and for the development of any future vaccination campaign to prevent SARS-CoV-2 infection. METHODS: Using a highly specific and sensitive measurement of antibodies by fluid-phase luciferase immunoprecipitation assays, we characterised the IgG, IgM and IgA response against multiple antigens of SARS-CoV-2 in a cohort of 509 patients with documented diagnosis of COVID-19, prospectively followed at our institution. We analysed clinical outcomes and antibody titres according to the presence of hyperglycaemia, i.e., either diagnosed or undiagnosed diabetes, at the time of, or during, hospitalisation. RESULTS: Among patients with confirmed COVID-19, 139 (27.3%) had diabetes: 90 (17.7%) had diabetes diagnosed prior to the hospital admission (comorbid diabetes) while 49 (9.6%) had diabetes diagnosed at the time of admission (newly diagnosed). Diabetes was associated with increased levels of inflammatory biomarkers and hypercoagulopathy, as well as leucocytosis and neutrophilia. Diabetes was independently associated with risk of death (HR 2.32 [95% CI 1.44, 3.75], p = 0.001), even after adjustment for age, sex and other relevant comorbidities. Moreover, a strong association between higher glucose levels and risk of death was documented irrespective of diabetes diagnosis (HR 1.14 × 1.1 mmol/l [95% CI 1.08, 1.21], p < 0.001). The humoral response against SARS-CoV-2 in patients with diabetes was present and superimposable, as for timing and antibody titres, to that of non-diabetic patients, with marginal differences, and was not influenced by glucose levels. Of the measured antibody responses, positivity for IgG against the SARS-CoV-2 spike receptor-binding domain (RBD) was predictive of survival rate, both in the presence or absence of diabetes. CONCLUSIONS/INTERPRETATION: The observed increased severity and mortality risk of COVID-19 pneumonia in patients with hyperglycaemia was not the result of an impaired humoral response against SARS-CoV-2. RBD IgG positivity was associated with a remarkable protective effect, allowing for a cautious optimism about the efficacy of future vaccines against SARs-COV-2 in people with diabetes. Graphical abstract.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Lampasona V, Secchi M, Scavini M, et al. Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study. Diabetologia. 2020. PMID: 33029657. doi:10.1007/s00125-020-05284-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。